The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday newspaper round-up: GlaxoSmithKline, Rare Earths, Amazon

Sun, 02nd May 2021 12:32

(Sharecast News) - Top investors in Glaxo Smith Kline are piling pressure on Dame Emma Walmsley after the activist New York hedge fund Elliott Management was revealed to have built a significant stake. Two top-20 investors in the drugs and consumer goods giant said that the chief executive's future was in doubt after four years of disappointing performance. One top-20 investor said there was "no desire to protect her" among institutional shareholders. Another said that Walmsley, 51, should step aside after her plan to break the business in two is carried out and hand over to her lieutenant, Luke Miels. - Sunday Times
Fears China will "turn off the taps" on Britain's green revolution has forced ministers to enter secret talks with seven commonwealth countries to mine their rare earths. Officials from the Department of International Trade and the Foreign Office have had meetings with representatives from Australia, Canada, Malawi and Tanzania in a bid to persuade them to supply rare earths, as well as critical metals such as lithium to the UK. Rare earths are found in abundance across the world, but are difficult to process and China controls around 90 per cent of the market. - Sunday Telegraph

Amazon is poised to seize upon the recent surge in interest in cryptocurrencies, bringing in a team of British financial regulation experts amid speculation it is on the brink of launching its own digital token. The US tech giant is understood to have poached at least six regulatory specialists from UK banking watchdog the Financial Conduct Authority (FCA) in the past two years. At least four of those have joined in the past year, taking up roles including public policy manager for regulation and chief compliance officer for payments divisions. - Sunday Telegraph

Britain will overtake Germany to become the largest economy in Europe by 2050, Transport Secretary Grant Shapps is predicting. He said Brexit has given Britain 'huge economic freedoms' to boost growth and he said he is putting aviation 'right at the heart' of the Government's mission to create Global Britain. - Financial Mail on Sunday

In another torrid year for the aviation industry, the coming month of May offers a little hope. The red-letter day in every UK airline executive's diary is 17 May, from which international leisure travel from Britain may be permitted. This week, ministers may finally divulge where and when holidaymakers can go, with a "green list" of countries that can be visited without quarantine on return. The Department for Transport insists it is on track to confirm, by "early May" as promised, whether planes can take off, and where to. - Guardian

Fund manager Ruffer has sold the majority of its holding in Bitcoin after Twitter posts by billionaire entrepreneur Elon Musk sent the price of the cryptocurrency soaring, The Mail on Sunday can reveal. Ruffer, a conservative asset management firm, surprised the City in November when it put 2.5 per cent of its customers' money - worth $600million (£433million) at the time - into Bitcoin. - Financial Mail on Sunday

Cosworth, the engineering firm best-known for producing powerful engines for high-performance Fords in the 1980s, is racing towards a float expected to value it at more than £100m. The Northamptonshire-based business has appointed Peel Hunt to advise on a stock market debut in London as soon as this summer. Cosworth, which employs almost 500 in the UK, Europe and North America, is part-owned by Kevin Kalkhoven, an Australian venture capitalist and motorsport entrepreneur, who bought the company from Ford in 2004 with his business partner Gerald Forsythe. - Sunday Telegraph

He has taken a battering for changing the name of FTSE100 funds giant Standard Life Aberdeen to Abrdn. But last night, chief executive Stephen Bird hit back, telling The Mail on Sunday that traditional fund management is 'in decline' - and revealing that the rebrand is part of a major strategy shift. The fund group, which manages £535billion, was mocked last week when it unveiled Abrdn. - Financial Mail on Sunday

Millions of employees could be given the chance to switch permanently to more flexible working arrangements under forthcoming guidance designed to encourage firms to make long-term some of the emergency changes ushered in by the pandemic. The government's flexible working taskforce is drawing up guidance - before the expected lifting of the remaining lockdown restrictions, including the requirement to work from home, on 21 June - to support the emergence of new, hybrid ways of working. For example, staff might come into offices only occasionally and work at home or at a neighbourhood cafe for the rest of the week. - Guardian
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.